Physician profile
Michael Adashek
NPI 1972037661
$3,440.13
in general payments reported to CMS, 2019-2025
39 companies · $2,061 in 2025
The $2,061 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $385 · 2024: $994 · 2025: $2,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,333 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,332.61 |
| Education | $107.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $611.84 | 2023-2025 | Erleada, Tecvayli, Carvykti |
| Astrazeneca Pharmaceuticals LP | $211.63 | 2023-2025 | Lynparza, Imfinzi, Calquence |
| Bayer Healthcare Pharmaceuticals INC. | $195.99 | 2025 | |
| Dendreon Pharmaceuticals LLC | $191.13 | 2025 | Provenge |
| E.R. Squibb & Sons, L.L.C. | $184.75 | 2024-2025 | Opdivo, Opdualag, Augtyro |
| Ferring Pharmaceuticals INC. | $154.77 | 2025 | Adstiladrin |
| Glaxosmithkline, LLC. | $154.55 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Pfizer INC. | $143.82 | 2024-2025 | |
| Tempus Ai, INC | $121.76 | 2024-2025 | Xt Cdx |
| Genentech USA, INC. | $114.43 | 2024 | Columvi, Polivy, Lunsumio |
| Lilly USA, LLC | $107.52 | 2023 | |
| Sumitomo Pharma America, INC. | $104.94 | 2025 | Orgovyx, Gemtesa |
| Merck Sharp & Dohme LLC | $99.80 | 2025 | Keytruda, Welireg |
| Alexion Pharmaceuticals, INC. | $87.32 | 2023-2024 | Ultomiris |
| Urogen Pharma, INC. | $76.42 | 2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $72.63 | 2025 | |
| Novartis Pharmaceuticals Corporation | $67.82 | 2023-2025 | |
| Astellas Pharma US INC | $65.35 | 2023-2025 | Xtandi |
| Exelixis INC. | $62.39 | 2025 | Cabometyx |
| Abbvie INC. | $52.77 | 2024 | |
| Eisai INC. | $50.51 | 2024 | |
| Endo USA, INC. | $47.86 | 2025 | Xiaflex, Aveed |
| Celgene Corporation | $47.59 | 2024 | Reblozyl |
| Stemline Therapeutics INC. | $45.71 | 2023-2025 | Elzonris, Orserdu |
| Gilead Sciences, INC. | $44.15 | 2025 | Trodelvy |
| Caris Mpi, INC. | $38.21 | 2025 | Mi Cancer Seek |
| Emd Serono, INC. | $32.06 | 2024 | |
| Blue Earth Diagnostics | $27.36 | 2025 | Posluma |
| Tolmar, INC. | $27.07 | 2025 | Jatenzo, Eligard |
| Accord Healthcare, INC. | $24.50 | 2025 | |
| Novo Nordisk INC | $24.37 | 2025 | Rivfloza |
| Immunitybio, INC. | $23.23 | 2025 | |
| Antares Pharma, INC. | $20.77 | 2025 | Xyosted |
| Vertex Pharmaceuticals Incorporated | $19.24 | 2025 | |
| Jazz Pharmaceuticals INC. | $19.22 | 2024 | |
| Tersera Therapeutics LLC | $17.60 | 2025 | Zoladex |
| Verity Pharmaceuticals INC. | $17.36 | 2025 | Trelstar |
| Civco Medical Instruments | $16.06 | 2025 | |
| Amgen INC. | $15.63 | 2023 | Xgeva, Vectibix, Nplate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Adashek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.